Arcus Biosciences, Inc. (RCUS) Stock Analysis

Arcus Biosciences, Inc. (RCUS) Stock Analysis — AI Research | MarketCI

RCUS

Market Closed

Arcus Biosciences, Inc.

NYSEHealthcare Biotechnology

627 employees

CEO: Terry J. Rosen

Founded: 2018

$23.80

+$0.00(+NaN%)

Market Cap

2.40B

Beta

0.84

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

RCUS Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for RCUS built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Strong Sell

Pass %

42.86%

Score

3/7

Fair Value Estimate

Cash flow analysis • Multiple methods

-$38.72

AI Price Target

Machine learning • Price prediction

$25.12

Market Sentiment

News & social media analysis

0.00

Value Investor Price

Classic value analysis

$0.00

Financial Health

Bankruptcy risk assessment

0.54

Quality Score

Financial strength rating

1.00

AI Investment Grade

Deep analysis of filings & news

65.00

Key Investment Highlights

Important factors affecting RCUS investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

33.33% Poor

Conditions Met

13.00/39.00

Due Diligence Score

33.33%

Due Diligence Conditions

Investment analysis conditions and results


	Fail
	Pass
	Fail
	Fail
	Pass
	Fail

Showing 1 to 6 of 46 conditions